Literature DB >> 23404781

Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis.

Salvatore Calanna1, Salvatore Piro, Antonino Di Pino, Rose Maria Zagami, Francesca Urbano, Francesco Purrello, Agata Maria Rabuazzo.   

Abstract

OBJECTIVE: Obesity is widely acknowledged as a critical risk factor for metabolic complications. Among obese subjects, there is a phenotype of metabolically healthy but obese (MHO) individuals that shows a favorable cardiometabolic risk profile. We aimed to evaluate the potential mechanisms underlying the metabolic profile of this subset, including alpha and beta cell function and entero-insular axis. DESIGN AND METHODS: One hundred twenty-nine obese and 24 nonobese subjects were studied. Obese participants were defined as MHO or at-risk obese, according to the homeostasis model of assessment-insulin resistance (HOMA-IR) index (MHO: lower tertile of HOMA-IR, n = 43; at-risk: upper tertile of HOMA-IR index, n = 41). Insulin, glucagon, and incretin responses after a 120' oral glucose tolerance test (75-g OGTT) were investigated.
RESULTS: During OGTT, MHO individuals showed in comparison with at-risk subjects: lower fasting and afterloads plasma levels of glucose, insulin, and C-peptide; higher disposition index; lower fasting (P = 0.004) and at 30' (P = 0.01) plasma glucose-dependent insulinotropic polypeptide (GIP) levels; lower area under the curve (AUC) (0-30) for GIP (P = 0.008); higher glucagon-like peptide-1 (GLP-1) plasma levels at 90' (P = 0.02) and 120' (P = 0.02); lower glucagon plasma levels at baseline (P = 0.04) and at 30' (P = 0.03); and appropriate glucagon suppression after the oral glucose load.
CONCLUSIONS: MHO subjects show, as well as normal-weight individuals, a lower diabetogenic profile by virtue of higher disposition index and unaffected entero-insular axis. At-risk obese individuals present increased GIP levels that might play a role in determining increased glucagon secretion and inappropriate glucagon responses after glucose load, thus contributing to impaired glucose homeostasis.
Copyright © 2012 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404781     DOI: 10.1002/oby.20017

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  8 in total

1.  Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.

Authors:  Natasha C Bergmann; Asger Lund; Lærke S Gasbjerg; Emma C E Meessen; Maria M Andersen; Sigrid Bergmann; Bolette Hartmann; Jens J Holst; Lene Jessen; Mikkel B Christensen; Tina Vilsbøll; Filip K Knop
Journal:  Diabetologia       Date:  2019-01-25       Impact factor: 10.122

Review 2.  New obesity classification criteria as a tool for bariatric surgery indication.

Authors:  Antonino De Lorenzo; Laura Soldati; Francesca Sarlo; Menotti Calvani; Nicola Di Lorenzo; Laura Di Renzo
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 3.  Dietary Interventions and Changes in Cardio-Metabolic Parameters in Metabolically Healthy Obese Subjects: A Systematic Review with Meta-Analysis.

Authors:  Marta Stelmach-Mardas; Jarosław Walkowiak
Journal:  Nutrients       Date:  2016-07-28       Impact factor: 5.717

4.  Pancreatic alpha-cells from female mice undergo morphofunctional changes during compensatory adaptations of the endocrine pancreas to diet-induced obesity.

Authors:  Beatriz Merino; Paloma Alonso-Magdalena; Mónica Lluesma; Patricia Ñeco; Alejandro Gonzalez; Laura Marroquí; Marta García-Arévalo; Angel Nadal; Ivan Quesada
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

5.  Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells.

Authors:  Salvatore Piro; Loriana G Mascali; Francesca Urbano; Agnese Filippello; Roberta Malaguarnera; Salvatore Calanna; Agata M Rabuazzo; Francesco Purrello
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

6.  Insulin-like growth factor-1 is a negative modulator of glucagon secretion.

Authors:  Elettra Mancuso; Gaia C Mannino; Concetta Di Fatta; Anastasia Fuoco; Rosangela Spiga; Francesco Andreozzi; Giorgio Sesti
Journal:  Oncotarget       Date:  2017-06-16

7.  Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy.

Authors:  Francesca Urbano; Antonino Di Pino; Roberto Scicali; Agnese Filippello; Stefania Di Mauro; Alessandra Scamporrino; Simona Marchisello; Agata Maria Rabuazzo; Francesco Purrello; Salvatore Piro
Journal:  Eur J Endocrinol       Date:  2019-12       Impact factor: 6.664

Review 8.  Cell Heterogeneity and Paracrine Interactions in Human Islet Function: A Perspective Focused in β-Cell Regeneration Strategies.

Authors:  Eva Bru-Tari; Daniel Oropeza; Pedro L Herrera
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.